Evaluation of renal transplantation recipients those who do not use steroid with panel reactive antibody and donor specific antibody

被引:0
|
作者
Tanrisev, Mehmet [1 ]
Ayna, Tulay Kilicaslan [2 ,3 ]
Colak, Hulya [1 ]
Yilmaz, Banu [1 ]
Ersan, Sibel [1 ]
Alp, Alper [4 ]
Tugmen, Cem [5 ]
Sert, Ismail [5 ]
Sevgili, Bahar Engin [6 ]
机构
[1] Izmir Tepecik Training & Res Hosp, Dept Nephrol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Fac Med, Dept Med Biol, Izmir, Turkey
[3] Izmir Tepecik Training & Res Hosp, Tissue Typing Lab, Izmir, Turkey
[4] Mugla Sitki Kocman Univ, Fac Med, Dept Nephrol, Mugla, Turkey
[5] Izmir Tepecik Training & Res Hosp, Dept Gen Surg, Izmir, Turkey
[6] Dursunbey State Hosp, Dept Internal Med, Balikesir, Turkey
来源
关键词
renal transplantation; corticosteroids; panel reactive antibody; donor specific antibody; HLA ANTIBODIES; MYCOPHENOLATE-MOFETIL; IMMUNOSUPPRESSION; WITHDRAWAL; MULTICENTER; AVOIDANCE; REJECTION; THERAPY;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Steroids are the mainstream drugs of immu-nosuppressive regimen in renal transplantation. They are successfully used on induction, maintenance and rejection treatment. Due to complications caused by steroids, treatments are switched to immunosuppressive agents. Graft dysfunction risk caused by reduced total immunosuppression disturbs clinicians very often. We documented the differences among patients by means of clinical presentation and PRA/DSA levels between patients who are using steroids and patients that were prescribed for steroid-free regimen. Methods: 82 individuals who did not use steroid and 52 patients on steroid treatment were included with similar rates of age, sex, primary renal disease, dialysis type, posttransplant follow-up duration and donor type. Pre and posttransplant PRA, DSA levels, posttransplant and current graft function and comorbidities were evaluated. Results: Individuals who do not use steroids were found to have a lower posttransplant creatinine level and glomerular filtration rate (GFR) compared to steroid users. Posttransplant and current spot urinary protein/creatinine rates were also lower in the steroid-free group. However DM, BKVN and induction therapy rates were higher in the steroid-free group. PRA and DSA levels were similar in both groups. On the other hand, posttransplant PRA-I levels were significantly higher in those with less steroid use time. Conclusions: Although steroid free regimens usually worry the clinicians, they can be preferred in patients with low immunological risk for rejection to avoid its side effects such as uncontrolled diabetes, obesity, musculoskeletal problems and cataracts.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [31] Evaluation and clinical validation of the Gen-Probe lifecodes donor specific antibody test in the setting of antibody incompatible transplantation
    Lavery, Gail
    Cullen, Katherine
    Clark, Brendan
    TISSUE ANTIGENS, 2010, 75 (05): : 579 - 579
  • [32] Transplantation of Donor Specific Antibody Positive, Crossmatch Negative (AHG/FCXM) Cardiac Allograft Recipients.
    Bogaev, Roberta
    George, Joggy
    Frazier, O. H.
    Etheridge, W. B.
    Raissi, Farshad
    Jacob, Leon
    Kar, Biswajit
    Delgado, Reynolds
    Loyalka, Pranav
    Gregoric, Igor
    Kerman, Ronald H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 247 - 247
  • [33] Elevated de novo donor specific antibody after alemtuzumab induction in renal transplant recipients.
    Jorgenson, Margaret
    Fose, Jillian
    Redfield, Robert
    Fabbri, Kassandra
    PHARMACOTHERAPY, 2016, 36 (07): : E103 - E104
  • [34] Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.
    Fabbri, K.
    Descourouez, J.
    Jorgenson, M.
    Redfield, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 619 - 619
  • [35] HLA Cw Donor Specific Antibodies Are Associated with Antibody-Mediated Rejection in Renal Transplantation
    Willicombe, M.
    Santos, E.
    Brookes, P.
    Saha, R.
    Galliford, J.
    McLean, A.
    Roufosse, C.
    Taube, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 415 - 415
  • [36] Occurrance of Donor Specific Antibody (DSA) within the First Year Post-Renal Transplantation
    Knight, Richard J.
    Land, Geoffrey
    Dilioglou, Smaroula
    Patel, Samir
    Achkar, Katafan
    Abdellatif, Abdul
    Gaber, Lillian
    Gaber, A. Osama
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 415 - 415
  • [37] Role of ExPlex HLA antibody panel in de novo HLA donor-specific antibody identification in kidney transplant recipients: 2 case reports
    Kendrick, J.
    Murrin, M.
    Dzion, J.
    Garabiles, E.
    Hardage, B.
    McCall, A.
    Patel, P.
    Robinson, Y.
    Santiago, R.
    Boasi, R.
    Williams, C.
    Du, Z.
    Elrefaei, M.
    HUMAN IMMUNOLOGY, 2023, 84 : 115 - 115
  • [38] RENAL-TRANSPLANTATION - CYCLOSPORINE-A AND ANTIBODY DEVELOPMENT AFTER DONOR-SPECIFIC TRANSFUSION
    ALMUZAIRAI, IA
    INNES, A
    HILLIS, A
    STEWART, KN
    BONE, JM
    CATTO, GRD
    MACLEOD, AM
    KIDNEY INTERNATIONAL, 1989, 35 (04) : 1057 - 1063
  • [39] Evaluation of the Effects of Simvastatin in Reduction of Panel-Reactive Antibody (PRA) Levels in Patients with End-Stage Renal Disease Awaiting Renal Transplantation
    Zahed, Nargesosadat
    Nazemian, Fatemeh
    Naghibi, Massih
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2012, 23 (02) : 306 - 310
  • [40] HLA Typing, Panel Reactive Antibody and Donor Specific Antigen Tests Are Not Necessary for Successful Parathyroid Allotransplantation.
    Kanimdan, E.
    Goncu, B.
    Gelmez, Y.
    Idiz, O.
    Toka, C.
    Ozdemir, B.
    Basoglu, H.
    Kandas, N. Ozten
    Yucesan, E.
    Ersoy, Y.
    Kazancioglu, R.
    Aysen, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 769 - 769